Takeda Pharmaceutical Co Ltd 2025 IR
The report outlines Takeda's progress and performance during fiscal year 2024, highlighting its commitment to patients, people, and the planet. Key achievements include advancing its late-stage clinical pipeline with six Phase 3 programs, expanding access to its dengue fever vaccine Qdenga in Latin America and Asia, and reducing Scope 1 and 2 greenhouse gas emissions by 55% compared to a 2016 baseline. Additionally, the company launched a company-wide program to drive further growth and improve efficiency.
Company: Takeda Pharmaceutical Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2025
Type: IR
Pages: 162
Back to company
Takeda Pharmaceutical Co Ltd
Annual Securities Report
The report outlines Takeda's progress and performance during fiscal year 2024, highlighting its commitment to patients, people, and the planet. Key achievements include advancing its late-stage clinical pipeline with six Phase 3 programs, expanding access to its dengue fever vaccine Qdenga in Latin America and Asia, and reducing Scope 1 and 2 greenhouse gas emissions by 55% compared to a 2016 baseline. Additionally, the company launched a company-wide program to drive further growth and improve efficiency.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Apr 1, 2024 - Mar 31, 2025
Fiscal Year
2024
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Net Zero Target
Employees